Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Ltd ADR (NQ: CNTB )

1.160 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.160
Bid (Size) 1.030 (1)
Ask (Size) 1.200 (1)
Prev. Close 1.160
Today's Range 1.160 - 1.160
52wk Range 0.6200 - 2.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product... 
Via Talk Markets

Performance

YTD
+34.88%
+34.88%
1 Month
+10.48%
+10.48%
3 Month
+0.87%
+0.87%
6 Month
+61.04%
+61.04%
1 Year
+45.00%
+45.00%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Cerberus Cyber Sentinel Shares Are Trading Higher By 147%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Connect Biopharma's Atopic Dermatitis Candidate Shows Rapid, Sustained Improvement Across All Body Regions
Via Benzinga
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
From Connect Biopharma Holdings Limited
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
From Connect Biopharma Holdings Limited
Via Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
From Connect Biopharma Holdings Limited
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Week In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong Exchange
Via Talk Markets
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.